Safely and well invested

Values & Performance of HAEMATO AG

Have you invested in HAEMATO AG or are you interested in the company's performance as a capital market participant? Here you will find all the important information about us and our activities: Current financial reports, key figures and our financial calendar.

Directly to the share price

€ 248 mio. sales in 2022

€ 1.20 per share dividend paid in 2023

635,000 packages sold annually

31 % sales CAGR since 2007

More than 7,000 customers

Ad-Hoc Mitteilung

Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the General Terms and Conditions of Deutsche Börse AG for the Open Market on the Frankfurt Stock Exchange (so-called delisting). The Management Board of the company will therefore send a corresponding letter of termination to Deutsche Börse AG today, November 30, 2023.

Upon expiry of the notice period, which is three months and thus ends at the end of February 2024 at the latest, trading of the company's shares on the Open Market (Basic Board) of the Frankfurt Stock Exchange will be discontinued. Until the end of the three-month period, the company's shareholders will continue to have the opportunity to trade their shares on the Regulated Unofficial Market of the Frankfurt Stock Exchange. The company's shares will no longer be traded on another stock exchange at the company's instigation after their inclusion in the open market of the Frankfurt Stock Exchange has ended.



HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". Further information can be found at

Rating & Research

Warburg Research

Buy: 33.00 €

First Berlin Equity Research

Buy: 34.00 €


Zum Aktienchart

Safely and well advised


Get an overview of the status and development of HAEMATO AG. Here you will find information about the group as well as the developments of the past years.

Read reports


We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

Investor News

In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2 million compared to the same period in 2022 (EUR 188.2 million). The result from ordinary activities (EBITDA) increased strongly by around 33% from EUR 7.7 million to EUR 10.2 million. The operating result (EBIT) even increased …

Ad-Hoc Mitteilung

Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to …

Investor News

HAEMATO AG has continued its profitable growth course in the new year and increased its revenue in the first half of 2023 by EUR 12.7 million compared to the same period in 2022 to EUR 133.64 million. This represents a growth in turnover of 10.5 % compared to the same period of the previous year.

Upcoming events

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us